Lv1
30 积分 2025-06-19 加入
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
20小时前
待确认
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
22小时前
已完结
The Art of Finding the Right Drug Target: Emerging Methods and Strategies
2个月前
已完结
皖公网安备34019202002308
